Brean Murray Gives Buy Rating to Medivation (MDVN)

By admin | 6 years ago

Medivation (NASDAQ: MDVN)‘s stock had its “buy” rating restated by equities researchers at Brean Murray in a report issued on Monday.

Shares of Medivation traded up 0.36% during mid-day trading on Monday, hitting $81.93. Medivation has a 52 week low of $14.32 and a 52 week high of $89.46. The company’s market cap is $2.970 billion.

Medivation last announced its earnings results on Tuesday, May 8th. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.19 by $1.18. The company’s revenue for the quarter was up 150.3% on a year-over-year basis. On average, analysts predict that Medivation will post $-0.70 earnings per share next quarter.

MDVN has been the subject of a number of other recent research reports. Analysts at Jefferies Group (NYSE: JEF) raised their price target on shares of Medivation to $105.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Finally, analysts at Summer Street raised their price target on shares of Medivation from $74.00 to $112.00 in a research note to investors on Wednesday, May 16th.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases for which there are limited treatment options.

About the author